BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998;26:205-213. [PMID: 9399837 DOI: 10.1093/nar/26.1.205] [Cited by in Crossref: 309] [Cited by in F6Publishing: 298] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Ruano-ravina A, Faraldo-vallés MJ, Barros-dios JM. Is there a specific mutation of p53 gene due to radon exposure? A systematic review. International Journal of Radiation Biology 2009;85:614-21. [DOI: 10.1080/09553000902954504] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
2 Potesil D, Mikelova R, Adam V, Kizek R, Prusa R. Change of the Protein p53 Electrochemical Signal According to its Structural Form – Quick and Sensitive Distinguishing of Native, Denatured, and Aggregated Form of the “Guardian of the Genome”. Protein J 2006;25:23-32. [DOI: 10.1007/s10930-006-0014-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
3 Aurelio ON, Kong XT, Gupta S, Stanbridge EJ. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 2000;20:770-8. [PMID: 10629033 DOI: 10.1128/MCB.20.3.770-778.2000] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mayr B, Blauensteiner J, Edlinger A, Reifinger M, Alton K, Schaffner G, Brem G. Presence of p53 mutations in feline neoplasms. Research in Veterinary Science 2000;68:63-9. [DOI: 10.1053/rvsc.1999.0339] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
5 Persson A, Bäckvall H, Pontén F, Uhlén M, Lundeberg J. Single cell gene mutation analysis using laser-assisted microdissection of tissue sections. Methods Enzymol 2002;356:334-43. [PMID: 12418212 DOI: 10.1016/s0076-6879(02)56947-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Bodai L, Pardi N, Ujfaludi Z, Bereczki O, Komonyi O, Balint E, Boros IM. Daxx-like protein of Drosophila interacts with Dmp53 and affects longevity and Ark mRNA level. J Biol Chem 2007;282:36386-93. [PMID: 17933869 DOI: 10.1074/jbc.M705547200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
7 Milićević Z, Bajić V, Živković L, Kasapović J, Andjelković U, Spremo-Potparević B. Identification of p53 and its isoforms in human breast carcinoma cells. ScientificWorldJournal 2014;2014:618698. [PMID: 24511294 DOI: 10.1155/2014/618698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
8 Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001;19:1405-13. [PMID: 11230485 DOI: 10.1200/JCO.2001.19.5.1405] [Cited by in Crossref: 204] [Cited by in F6Publishing: 74] [Article Influence: 9.7] [Reference Citation Analysis]
9 Wang X, Hou T, Lu T, Li F. Autonomous Exonuclease III-Assisted Isothermal Cycling Signal Amplification: A Facile and Highly Sensitive Fluorescence DNA Glycosylase Activity Assay. Anal Chem 2014;86:9626-31. [DOI: 10.1021/ac502125z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
10 Yamada Y, Oghiso Y, Morlier J, Guillet K, Fritsch P, Dudoignon N, Monchaux G. Comparative Study on Tp53 Gene Mutations in Lung Tumors from Rats Exposed to 239Pu, 237Np and 222Rn. JRR 2004;45:69-76. [DOI: 10.1269/jrr.45.69] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Müller-Ladner U, Nishioka K. p53 in rheumatoid arthritis: friend or foe? Arthritis Res 2000;2:175-8. [PMID: 11094424 DOI: 10.1186/ar82] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
12 Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289-98. [PMID: 12086865 DOI: 10.1016/s1535-6108(02)00047-8] [Cited by in Crossref: 348] [Cited by in F6Publishing: 175] [Article Influence: 17.4] [Reference Citation Analysis]
13 van der Weyden L, Adams DJ. Cancer of mice and men: old twists and new tails. J Pathol 2013;230:4-16. [PMID: 23436574 DOI: 10.1002/path.4184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Laine A, Topisirovic I, Zhai D, Reed JC, Borden KL, Ronai Z. Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 2006;26:8901-13. [PMID: 17000756 DOI: 10.1128/MCB.01156-06] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
15 D'erchia A, Pesole G, Tullo A, Saccone C, Sbisà E. Guinea Pig p53 mRNA: Identification of New Elements in Coding and Untranslated Regions and Their Functional and Evolutionary Implications. Genomics 1999;58:50-64. [DOI: 10.1006/geno.1999.5794] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
16 Popanda O, Zheng C, Magdeburg JR, Büttner J, Flohr T, Hagmüller E, Thielmann HW. Mutation analysis of replicative genes encoding the large subunits of DNA polymerase alpha and replication factors A and C in human sporadic colorectal cancers. Int J Cancer 2000;86:318-24. [PMID: 10760817 DOI: 10.1002/(sici)1097-0215(20000501)86:3<318::aid-ijc3>3.0.co;2-b] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
17 Jongmans W, Hall J. Cellular responses to radiation and risk of breast cancer. European Journal of Cancer 1999;35:540-8. [DOI: 10.1016/s0959-8049(98)00414-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Seo KY, Jelinsky SA, Loechler EL. Factors that influence the mutagenic patterns of DNA adducts from chemical carcinogens. Mutat Res 2000;463:215-46. [PMID: 11018743 DOI: 10.1016/s1383-5742(00)00047-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
19 Maurer CC, Syrigos KN. Biology of Tobacco and Smoking. In: Syrigos KN, Nutting CM, Roussos C, editors. Tumors of the Chest. Springer Berlin Heidelberg; 2006. pp. 23-39. [DOI: 10.1007/3-540-31040-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Warnecke PM, Bestor TH. Cytosine methylation and human cancer: . Current Opinion in Oncology 2000;12:68-73. [DOI: 10.1097/00001622-200001000-00012] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 3.5] [Reference Citation Analysis]
21 Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 2002;13:453-64. [PMID: 12499239 DOI: 10.1177/154411130201300603] [Cited by in Crossref: 107] [Cited by in F6Publishing: 98] [Article Influence: 5.6] [Reference Citation Analysis]
22 Joshi M, Ayoola A, Belani CP. Small-cell lung cancer: an update on targeted therapies. Adv Exp Med Biol 2013;779:385-404. [PMID: 23288650 DOI: 10.1007/978-1-4614-6176-0_18] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
23 Saha SP, Bhalla DK, Whayne TF Jr, Gairola C. Cigarette smoke and adverse health effects: An overview of research trends and future needs. Int J Angiol 2007;16:77-83. [PMID: 22477297 DOI: 10.1055/s-0031-1278254] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
24 South A, Ashton G, Willoughby C, Ellis I, Bleck O, Hamada T, Mannion G, Wessagowit V, Hashimoto T, Eady R, Mcgrath J. EEC (Ectrodactyly, Ectodermal dysplasia, Clefting) syndrome: heterozygous mutation in the p63 gene (R279H) and DNA-based prenatal diagnosis. Br J Dermatol 2002;146:216-20. [DOI: 10.1046/j.1365-2133.2002.04638.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
25 Naômé A, Schyman P, Laaksonen A, Vercauteren DP. Molecular Dynamics Simulation of 8-Oxoguanine Containing DNA Fragments Reveals Altered Hydration and Ion Binding Patterns. J Phys Chem B 2010;114:4789-801. [DOI: 10.1021/jp1000539] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
26 Kösel S, Scheithauer BW, Graeber MB. Genotype-Phenotype Correlation in Gemistocytic Astrocytomas: . Neurosurgery 2001;48:187-94. [DOI: 10.1227/00006123-200101000-00033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Eischen CM, Alt JR, Wang P. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 2004;23:8931-40. [DOI: 10.1038/sj.onc.1208052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
28 Imanishi M, Yamamoto Y, Wang X, Sugaya A, Hirose M, Endo S, Natori Y, Yamato K, Hyodo I. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells. Cancer Sci 2019;110:639-49. [PMID: 30488540 DOI: 10.1111/cas.13893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
29 Itoh T, O'Shea C, Linn S. Impaired regulation of tumor suppressor p53 caused by mutations in the xeroderma pigmentosum DDB2 gene: mutual regulatory interactions between p48(DDB2) and p53. Mol Cell Biol. 2003;23:7540-7553. [PMID: 14560002 DOI: 10.1128/MCB.23.21.7540-7553.2003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
30 Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, Li JL. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China. World J Gastroenterol 2003; 9(1): 16-21 [PMID: 12508343 DOI: 10.3748/wjg.v9.i1.16] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
31 Ogasawara S, Fujimoto K. SNP Genotyping by Using Photochemical Ligation. Angew Chem Int Ed 2006;45:4512-5. [DOI: 10.1002/anie.200600790] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
32 Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013;12:877-83. [PMID: 23428903 DOI: 10.4161/cc.24034] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
33 Walters JJ, Muhammad W, Fox KF, Fox A, Xie D, Creek KE, Pirisi L. Genotyping single nucleotide polymorphisms using intact polymerase chain reaction products by electrospray quadrupole mass spectrometry. Rapid Commun Mass Spectrom 2001;15:1752-9. [PMID: 11555877 DOI: 10.1002/rcm.435] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
34 Drexler HG, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff CC. p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? Leukemia 2000;14:198-206. [PMID: 10637496 DOI: 10.1038/sj.leu.2401604] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
35 Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 2012;120:5118-27. [PMID: 23018641 DOI: 10.1182/blood-2012-05-356014] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 7.7] [Reference Citation Analysis]
36 Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5. [PMID: 16141321 DOI: 10.1073/pnas.0506230102] [Cited by in Crossref: 871] [Cited by in F6Publishing: 806] [Article Influence: 51.2] [Reference Citation Analysis]
37 Monti P, Inga A, Scott G, Aprile A, Campomenosi P, Menichini P, Ottaggio L, Viaggi S, Abbondandolo A, Burns PA, Fronza G. 5-Methylcytosine at HpaII sites in p53 is not hypermutable after UVC irradiation. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999;431:93-103. [DOI: 10.1016/s0027-5107(99)00187-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126. [PMID: 10341712 DOI: 10.1002/(SICI)1096-9896(199901)187:1%3C112::AID-PATH250%3E3.0.CO;2-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Šebera J, Trantírek L, Tanaka Y, Sychrovský V. Pyramidalization of the glycosidic nitrogen provides the way for efficient cleavage of the N-glycosidic bond of 8-OxoG with the hOGG1 DNA repair protein. J Phys Chem B 2012;116:12535-44. [PMID: 22989268 DOI: 10.1021/jp309098d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
40 Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell DC, Guernsey JR, Guernsey DL, McLaughlin J. Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev. 2003;27:139-146. [PMID: 12670526 DOI: 10.1016/s0361-090x(03)00033-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
41 Chappell WH, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Rakus D, Gizak A, Terrian D, Steelman LS, McCubrey JA. Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. Adv Biol Regul 2016;60:64-87. [PMID: 26525204 DOI: 10.1016/j.jbior.2015.10.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
42 Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001;92:386-94. [DOI: 10.1002/1097-0142(20010715)92:2<386::aid-cncr1334>3.0.co;2-v] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
43 Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin–proteasome system. Seminars in Cancer Biology 2003;13:59-67. [DOI: 10.1016/s1044-579x(02)00100-1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
44 Ogasawara S, Fujimoto K. SNP Genotyping by Using Photochemical Ligation. Angew Chem 2006;118:4624-7. [DOI: 10.1002/ange.200600790] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
45 Rusin M, Butkiewicz D, Malusecka E, Zborek A, Harasim J, Czyzewski K, Bennett WP, Shields PG, Weston A, Welsh JA, Krzyzowska-Gruca S, Chorazy M, Harris CC. Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland. Br J Cancer 1999;80:1445-52. [PMID: 10424749 DOI: 10.1038/sj.bjc.6690542] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
46 Makino R, Kaneko K, Kurahashi T, Matsumura T, Mitamura K. Detection of mutation of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and an automated DNA sequencer in a large number of DNA samples. Mutat Res. 2000;452:83-90. [PMID: 10894894 DOI: 10.1016/S0027-5107(00)00056-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
47 Węsierska-gądek J. Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53’s tumor suppression. Future Medicinal Chemistry 2018;10:755-77. [DOI: 10.4155/fmc-2017-0175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
48 McCullough AK, Lloyd RS. Mechanisms underlying aflatoxin-associated mutagenesis - Implications in carcinogenesis. DNA Repair (Amst) 2019;77:76-86. [PMID: 30897375 DOI: 10.1016/j.dnarep.2019.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
49 Cole AR, Ji H, Simpson RJ. Proteomic analysis of colonic crypts from normal, multiple intestinal neoplasia andp53—null mice: A comparison with colonic polyps. Electrophoresis 2000;21:1772-81. [DOI: 10.1002/(sici)1522-2683(20000501)21:9<1772::aid-elps1772>3.0.co;2-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
50 Stary A, Sarasin A. [15] Ultraviolet A- and singlet oxygen-induced mutation spectra. Singlet Oxygen, UV-A, and Ozone. Elsevier; 2000. pp. 153-65. [DOI: 10.1016/s0076-6879(00)19017-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Brázda V, Jagelská EB, Fojta M, Palecek E. Searching for target sequences by p53 protein is influenced by DNA length. Biochem Biophys Res Commun 2006;341:470-7. [PMID: 16426567 DOI: 10.1016/j.bbrc.2005.12.202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
52 Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods C, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, Mckeon F, Brunner HG, van Bokhoven H. Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome. Cell 1999;99:143-53. [DOI: 10.1016/s0092-8674(00)81646-3] [Cited by in Crossref: 478] [Cited by in F6Publishing: 173] [Article Influence: 20.8] [Reference Citation Analysis]
53 Heidari N, Goliaei B, Moghaddam PR, Rahbar-Roshandel N, Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 2007;18:1139-47. [PMID: 17893514 DOI: 10.1097/CAD.0b013e3282eea257] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
54 Ruano-Ravina A, Pérez-Becerra R, Fraga M, Kelsey KT, Barros-Dios JM. Analysis of the relationship between p53 immunohistochemical expression and risk factors for lung cancer, with special emphasis on residential radon exposure. Ann Oncol 2008;19:109-14. [PMID: 17897960 DOI: 10.1093/annonc/mdm395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
55 Campomenosi P, Hall PA. Gadd45 mutations are uncommon in human tumour cell lines. Cell Prolif 2000;33:301-6. [PMID: 11063132 DOI: 10.1046/j.1365-2184.2000.00187.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
56 Al-Gabri NA, Saghir SAM, Al-Hashedi SA, El-Far AH, Khafaga AF, Swelum AA, Al-Wajeeh AS, Mousa SA, Abd El-Hack ME, Naiel MAE, El-Tarabily KA. Therapeutic Potential of Thymoquinone and Its Nanoformulations in Pulmonary Injury: A Comprehensive Review. Int J Nanomedicine 2021;16:5117-31. [PMID: 34349511 DOI: 10.2147/IJN.S314321] [Reference Citation Analysis]
57 Giglia G, Bouffet E, Jouvet A, Ohgaki H, Kleihues P, Sarasin A. Molecular analysis of glioma and skin-tumour alterations in a xeroderma-pigmentosum child. Int J Cancer 1999;81:345-50. [PMID: 10209947 DOI: 10.1002/(sici)1097-0215(19990505)81:3<345::aid-ijc6>3.0.co;2-e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A 1999;96:4494-9. [PMID: 10200290 DOI: 10.1073/pnas.96.8.4494] [Cited by in Crossref: 313] [Cited by in F6Publishing: 275] [Article Influence: 13.6] [Reference Citation Analysis]
59 Brisuda A, Háček J, Čechová M, Škapa P, Babjuk M. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM 5, MCM 2 and Ki‐67 antibodies using cell blocks derived from urine. Cytopathology 2019;30:510-8. [DOI: 10.1111/cyt.12698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87:14-32. [PMID: 18096889 DOI: 10.1177/154405910808700104] [Cited by in Crossref: 259] [Cited by in F6Publishing: 236] [Article Influence: 18.5] [Reference Citation Analysis]
61 Vidaurre T, Casavilca S, Montenegro P, Gomez H, Calderón M, Navarro J, Aramburu J, Poquioma E, Tsuchiya Y, Asai T, Ajioka Y, Sato A, Ikoma T, Nakamura K. Tumor Protein p53 and K-ras Gene Mutations in Peruvian Patients with Gallbladder Cancer. Asian Pac J Cancer Prev 2019;20:289-94. [PMID: 30678452 DOI: 10.31557/APJCP.2019.20.1.289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Buzek J, Latonen L, Kurki S, Peltonen K, Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 2002;30:2340-8. [PMID: 12034820 DOI: 10.1093/nar/30.11.2340] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 4.4] [Reference Citation Analysis]
63 Guerra E, Alberti S. Molecular Prognostic Indicators for Breast Cancer. Tumori 2001;87:23-5. [DOI: 10.1177/030089160108700637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
64 Kaneko K, Kurahashi T, Makino R, Konishi K, Ito H, Katagiri A, Kumekawa Y, Hirayama Y, Yoneyama K, Kushima M, Kusano M, Tajiri H, Rembacken BJ, Mitamura K, Imawari M. Pathological features and genetic alterations in colorectal carcinomas with characteristics of nonpolypoid growth. Br J Cancer 2004;91:312-8. [PMID: 15213719 DOI: 10.1038/sj.bjc.6601965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
65 Yamamoto K, Nakata D, Tada M, Tonoki H, Nishida T, Hirai A, Ba Y, Aoyama T, Hamada J, Furuuchi K, Harada H, Hirai K, Shibahara N, Katsuoka Y, Moriuchi T. A functional and quantitative mutational analysis of p53 mutations in yeast indicates strand biases and different roles of mutations in DMBA- and BBN-induced tumors in rats. Int J Cancer 1999;83:700-5. [PMID: 10521810 DOI: 10.1002/(sici)1097-0215(19991126)83:5<700::aid-ijc22>3.0.co;2-q] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Loukopoulos P, Thornton JR, Robinson WF. Clinical and pathologic relevance of p53 index in canine osseous tumors. Vet Pathol 2003;40:237-48. [PMID: 12724563 DOI: 10.1354/vp.40-3-237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
67 Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: Implications for imaging and management. Radiology. 2011;258:673-693. [PMID: 21339346 DOI: 10.1148/radiol.10100376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
68 Paci M, Rapicetta C, Maramotti S. New biomarkers for lung cancer. Expert Opin Med Diagn 2010;4:201-24. [PMID: 23488531 DOI: 10.1517/17530051003725113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
69 Asplund A, Sivertsson A, Backvall H, Ahmadian A, Lundeberg J, Ponten F. Genetic mosaicism in basal cell carcinoma. Exp Dermatol 2005;14:593-600. [DOI: 10.1111/j.0906-6705.2005.00333.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
70 Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001;97:3552-8. [PMID: 11369650 DOI: 10.1182/blood.v97.11.3552] [Cited by in Crossref: 67] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
71 Hamada H, Tashima Y, Kisaka Y, Iwamoto K, Hanai T, Eguchi Y, Okamoto M. Sophisticated framework between cell cycle arrest and apoptosis induction based on p53 dynamics. PLoS One 2009;4:e4795. [PMID: 19274075 DOI: 10.1371/journal.pone.0004795] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
72 Fen CX, Coomber DW, Lane DP, Ghadessy FJ. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. J Mol Biol 2007;371:1238-48. [PMID: 17610896 DOI: 10.1016/j.jmb.2007.05.099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
73 Fronza G, Inga A, Monti P, Scott G, Campomenosi P, Menichini P, Ottaggio L, Viaggi S, Burns PA, Gold B, Abbondandolo A. The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts. Mutat Res 2000;462:293-301. [PMID: 10767639 DOI: 10.1016/s1383-5742(00)00011-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
74 Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res. 2014;74:1153-1165. [PMID: 24247721 DOI: 10.1158/0008-5472.can-13-0955] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
75 Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 2002;99:10025-30. [PMID: 12119414 DOI: 10.1073/pnas.152333199] [Cited by in Crossref: 136] [Cited by in F6Publishing: 136] [Article Influence: 6.8] [Reference Citation Analysis]
76 Eapen AK, Henry MK, Quelle DE, Quelle FW. Dna damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol Cell Biol 2001;21:6113-21. [PMID: 11509654 DOI: 10.1128/MCB.21.18.6113-6121.2001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
77 Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH; Gynecologic Oncology Group. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Gynecol Oncol 2008;111:487-95. [PMID: 18834621 DOI: 10.1016/j.ygyno.2008.08.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
78 Dresios J, Panopoulos P, Synetos D. Eukaryotic ribosomal proteins lacking a eubacterial counterpart: important players in ribosomal function. Mol Microbiol 2006;59:1651-63. [PMID: 16553873 DOI: 10.1111/j.1365-2958.2006.05054.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 3.5] [Reference Citation Analysis]
79 Pavlopoulou A, Spandidos DA, Michalopoulos I. Human cancer databases (review). Oncol Rep 2015;33:3-18. [PMID: 25369839 DOI: 10.3892/or.2014.3579] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
80 Loeb KR, Asgari MM, Hawes SE, Feng Q, Stern JE, Jiang M, Argenyi ZB, de Villiers EM, Kiviat NB. Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas. PLoS One 2012;7:e34422. [PMID: 22545084 DOI: 10.1371/journal.pone.0034422] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
81 Malik A, Singh H, Andrabi M, Husain SA, Ahmad S. Databases and QSAR for Cancer Research. Cancer Inform 2006;2:117693510600200. [DOI: 10.1177/117693510600200002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
82 Nakamura H, Kawagishi H, Watanabe A, Sugimoto K, Maruyama M, Sugimoto M. Cooperative role of the RNA-binding proteins Hzf and HuR in p53 activation. Mol Cell Biol 2011;31:1997-2009. [PMID: 21402775 DOI: 10.1128/MCB.01424-10] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
83 Wang WH, Hullinger RL, Andrisani OM. Hepatitis B virus X protein via the p38 MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J Biol Chem. 2008;283:25455-25467. [PMID: 18606816 DOI: 10.1074/jbc.M801934200] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
84 Thilly WG. Have environmental mutagens caused oncomutations in people? Nat Genet 2003;34:255-9. [PMID: 12833049 DOI: 10.1038/ng1205] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 3.2] [Reference Citation Analysis]
85 Nia AB, Kleinjans JCS, Schooten FJV. Biomonitoring of tobacco smoke carcinogenicity by dosimetry of DNA adducts and genotyping and phenotyping of biotransformational enzymes: a review on polycyclic aromatic hydrocarbons. Biomarkers 2008;7:209-29. [DOI: 10.1080/13547500110120000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
86 Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004;23:4430-43. [PMID: 15077194 DOI: 10.1038/sj.onc.1207553] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 4.4] [Reference Citation Analysis]
87 Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-43. [PMID: 17409807 DOI: 10.1097/01.JTO.0000263718.69320.4c] [Cited by in Crossref: 194] [Cited by in F6Publishing: 110] [Article Influence: 12.9] [Reference Citation Analysis]
88 Rugge M, Shiao YH, Busatto G, Cassaro M, Strobbe C, Russo VM, Leo G, Parenti AR, Scapinello A, Arslan P. The p53 gene in patients under the age of 40 with gastric cancer: mutation rates are low but are associated with a cardiac location. Mol Pathol. 2000;53:207-210. [PMID: 11040944 DOI: 10.1136/mp.53.4.207] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
89 Ito S, Ohga T, Saeki H, Nakamura T, Watanabe M, Tanaka S, Kakeji Y, Maehara Y. p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. Int J Cancer 2005;113:22-8. [PMID: 15386362 DOI: 10.1002/ijc.20500] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
90 Martin AC, Facchiano AM, Cuff AL, Hernandez-boussard T, Olivier M, Hainaut P, Thornton JM. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002;19:149-64. [DOI: 10.1002/humu.10032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 4.4] [Reference Citation Analysis]
91 Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, Campo E, Delabie J, Gascoyne RD, Ott G, Rimsza L, Müller-Hermelink HK, Jaffe ES, Rosenwald A, Staudt LM, Chan WC, Greiner TC. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396-405. [PMID: 17881637 DOI: 10.1182/blood-2007-02-072082] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
92 Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K, Sekido Y. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer. 2004;100:1673-1682. [PMID: 15073856 DOI: 10.1002/cncr.20164] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]
93 Hori M, Suzuki K, Udono MU, Yamauchi M, Mine M, Watanabe M, Kondo S, Hozumi Y. Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism. Arch Dermatol Res 2009;301:631-46. [PMID: 19009304 DOI: 10.1007/s00403-008-0915-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
94 Pfeifer GP. p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 2000;450:155-66. [PMID: 10838140 DOI: 10.1016/s0027-5107(00)00022-1] [Cited by in Crossref: 118] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
95 Zhang X, Wang M, Zhou C, Chen S, Wang J. The expression of iASPP in acute leukemias. Leuk Res. 2005;29:179-183. [PMID: 15607367 DOI: 10.1016/j.leukres.2004.07.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 3.8] [Reference Citation Analysis]
96 Šebera J, Hattori Y, Sato D, Reha D, Nencka R, Kohno T, Kojima C, Tanaka Y, Sychrovský V. The mechanism of the glycosylase reaction with hOGG1 base-excision repair enzyme: concerted effect of Lys249 and Asp268 during excision of 8-oxoguanine. Nucleic Acids Res 2017;45:5231-42. [PMID: 28334993 DOI: 10.1093/nar/gkx157] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
97 Chen CP, Ganguly A, Wang CH, Hsu CW, Chattopadhyay S, Hsu YK, Chang YC, Chen KH, Chen LC. Label-free dual sensing of DNA molecules using GaN nanowires. Anal Chem 2009;81:36-42. [PMID: 19046071 DOI: 10.1021/ac800986q] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
98 Ikeda J, Tada M, Ishii N, Saya H, Tsuchiya K, Okaichi K, Mishima K, Sawamura Y, Fulci G, Liu TJ, Van Meir EG. Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis. Int J Cancer 2001;94:35-43. [PMID: 11668476 DOI: 10.1002/ijc.1431] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
99 Gonçalves AR, Carneiro AJ, Martins I, de Faria PA, Ferreira MA, de Mello EL, Fogaça HS, Elia CC, de Souza HS. Prognostic significance of p53 protein expression in early gastric cancer. Pathol Oncol Res 2011;17:349-55. [PMID: 21116760 DOI: 10.1007/s12253-010-9333-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
100 Hussain S, Harris CC. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutation Research/Reviews in Mutation Research 2000;462:311-22. [DOI: 10.1016/s1383-5742(00)00015-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
101 Hernandez-Boussard TM, Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect 1998;106:385-91. [PMID: 9637795 DOI: 10.1289/ehp.98106385] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 3.2] [Reference Citation Analysis]
102 Adega F, Borges A, Chaves R. Cat Mammary Tumors: Genetic Models for the Human Counterpart. Vet Sci 2016;3:E17. [PMID: 29056725 DOI: 10.3390/vetsci3030017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
103 Hoenerhoff MJ, Hong HH, Ton TV, Lahousse SA, Sills RC. A review of the molecular mechanisms of chemically induced neoplasia in rat and mouse models in National Toxicology Program bioassays and their relevance to human cancer. Toxicol Pathol 2009;37:835-48. [PMID: 19846892 DOI: 10.1177/0192623309351726] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
104 Voeltzel T, Morel AP, Rostan MC, Ji J, Chiodino C, Ponchel F, Vigouroux J, Caron De Fromentel C, Soussi T, Ozturk M. A New Set of Monoclonal Antibodies Directed to Proline-Rich and Central Regions of p53. Hybridoma and Hybridomics 2004;23:287-92. [DOI: 10.1089/hyb.2004.23.287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Pfeifer GP, Denissenko MF, Tang MS. PCR-based approaches to adduct analysis. Toxicol Lett 1998;102-103:447-51. [PMID: 10022294 DOI: 10.1016/s0378-4274(98)00337-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
106 Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int J Urol 2005;12:709-16. [PMID: 16174043 DOI: 10.1111/j.1442-2042.2005.01155.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
107 Hager JH, Hanahan D. Tumor Cells Utilize Multiple Pathways to Down-modulate Apoptosis: Lessons from a Mouse Model of Islet Cell Carcinogenesis. Annals of the New York Academy of Sciences 1999;887:150-63. [DOI: 10.1111/j.1749-6632.1999.tb07929.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
108 Zheng Y, Xue Y, Yan GS. The effects of oxidation and protonation on the N-glycosidic bond stability of 8-oxo-2′-deoxyguanosine: DFT study. Journal of Molecular Structure: THEOCHEM 2008;860:52-7. [DOI: 10.1016/j.theochem.2008.03.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
109 Capoulade C, Mir LM, Carlier K, Lécluse Y, Tétaud C, Mishal Z, Wiels J. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood 2001;97:1043-9. [PMID: 11159535 DOI: 10.1182/blood.v97.4.1043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
110 Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-26. [DOI: 10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3] [Cited by in Crossref: 845] [Cited by in F6Publishing: 292] [Article Influence: 36.7] [Reference Citation Analysis]
111 Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T, van Beersum SE, Gorlin R, Murray JC. Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts. J Med Genet 2002;39:559-66. [PMID: 12161593 DOI: 10.1136/jmg.39.8.559] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
112 Jagelská E, Brázda V, Pospisilová S, Vojtesek B, Palecek E. New ELISA technique for analysis of p53 protein/DNA binding properties. J Immunol Methods 2002;267:227-35. [PMID: 12165443 DOI: 10.1016/s0022-1759(02)00182-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
113 Ong HJ, Siau JW, Zhang JB, Hong M, Flotow H, Ghadessy F. Analysis of p53 binding to DNA by fluorescence imaging microscopy. Micron 2012;43:996-1000. [PMID: 22537717 DOI: 10.1016/j.micron.2012.03.024] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Smukste I, Bhalala O, Persico M, Stockwell BR. Using small molecules to overcome drug resistance induced by a viral oncogene. Cancer Cell 2006;9:133-46. [PMID: 16473280 DOI: 10.1016/j.ccr.2006.01.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
115 Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, Wang M, Wang J. Identification of a Novel Isoform of iASPP and its Interaction with p53. Journal of Molecular Biology 2007;368:1162-71. [DOI: 10.1016/j.jmb.2007.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
116 Pütz A, Hartmann AA, Fontes PR, Alexandre CO, Silveira DA, Klug SJ, Rabes HM. TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors. Int J Cancer 2002;98:99-105. [PMID: 11857392 DOI: 10.1002/ijc.10128] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
117 Moergel M, Goldschmitt J, Stockinger M, Kunkel M. ΔNp63 expression in four carcinoma cell lines and the effect on radioresistance—a siRNA knockdown model. Clin Oral Invest 2014;18:1259-68. [DOI: 10.1007/s00784-013-1078-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
118 Knights CD, Liu Y, Appella E, Kulesz-martin M. Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification. Journal of Biological Chemistry 2003;278:52890-900. [DOI: 10.1074/jbc.m300279200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
119 Kaneko K, Akuta T, Sawa T, Kim HW, Fujii S, Okamoto T, Nakayama H, Ohigashi H, Murakami A, Akaike T. Mutagenicity of 8-nitroguanosine, a product of nitrative nucleoside modification by reactive nitrogen oxides, in mammalian cells. Cancer Lett 2008;262:239-47. [PMID: 18248787 DOI: 10.1016/j.canlet.2007.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
120 Topisirovic I, Gutierrez GJ, Chen M, Appella E, Borden KL, Ronai ZA. Control of p53 multimerization by Ubc13 is JNK-regulated. Proc Natl Acad Sci U S A 2009;106:12676-81. [PMID: 19651615 DOI: 10.1073/pnas.0900596106] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
121 Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, Lambert B, Hou SM. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005;113:761-8. [PMID: 15499621 DOI: 10.1002/ijc.20650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
122 Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M, Shimizu K, Tanaka N, Jass JR, Matsubara N. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007;56:13-9. [PMID: 16785283 DOI: 10.1136/gut.2005.089813] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
123 Guerra E, Vacca G, Palombo B, Alberti S. Prognostic Value of Mutations in TP53 and RAS Genes in Breast Cancer. Int J Biol Markers 2003;18:49-53. [DOI: 10.1177/172460080301800108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(5): 606-609 [DOI: 10.11569/wcjd.v11.i5.606] [Reference Citation Analysis]
125 Neukirchen J, Meier A, Rohrbeck A, Garcia-Pardillos G, Steidl U, Fenk R, Haas R, Kronenwett R, Rohr UP. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther 2007;14:431-9. [PMID: 17235352 DOI: 10.1038/sj.cgt.7701029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
126 Aubert M, Blaho JA. Viral oncoapoptosis of human tumor cells. Gene Ther 2003;10:1437-45. [PMID: 12900758 DOI: 10.1038/sj.gt.3302004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
127 Jefferies S, Foulkes W. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncology 2001;37:115-26. [DOI: 10.1016/s1368-8375(00)00065-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
128 Blaho JA. Oncoapoptosis: a novel molecular therapeutic for cancer treatment. IUBMB Life 2010;62:87-91. [PMID: 19937971 DOI: 10.1002/iub.274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Walters B, Thompson SR. Cap-Independent Translational Control of Carcinogenesis. Front Oncol 2016;6:128. [PMID: 27252909 DOI: 10.3389/fonc.2016.00128] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
130 Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000;89:92-9. [PMID: 10719737 DOI: 10.1002/(sici)1097-0215(20000120)89:1<92::aid-ijc15>3.0.co;2-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
131 McCulloch SD, Kokoska RJ, Garg P, Burgers PM, Kunkel TA. The efficiency and fidelity of 8-oxo-guanine bypass by DNA polymerases delta and eta. Nucleic Acids Res 2009;37:2830-40. [PMID: 19282446 DOI: 10.1093/nar/gkp103] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
132 Tani M, Shimizu K, Kawahara C, Kohno T, Ishimoto O, Ikawa S, Yokota J. Mutation and expression of the p51 gene in human lung cancer. Neoplasia 1999;1:71-9. [PMID: 10935472 DOI: 10.1038/sj.neo.7900008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
133 Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang Z, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999;431:199-209. [DOI: 10.1016/s0027-5107(99)00162-1] [Cited by in Crossref: 140] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
134 Ono T, Ikehata H, Nakamura S, Saito Y, Hosoi Y, Takai Y, Yamada S, Onodera J, Yamamoto K. Age-associated increase of spontaneous mutant frequency and molecular nature of mutation in newborn and old lacZ-transgenic mouse. Mutat Res 2000;447:165-77. [PMID: 10751600 DOI: 10.1016/s0027-5107(99)00200-6] [Cited by in Crossref: 73] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
135 Li Y, Melnikov AA, Levenson V, Guerra E, Simeone P, Alberti S, Deng Y. A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer 2015;15:417. [PMID: 25986046 DOI: 10.1186/s12885-015-1412-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
136 You YH, Pfeifer GP. Similarities in sunlight-induced mutational spectra of CpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J Mol Biol 2001;305:389-99. [PMID: 11152598 DOI: 10.1006/jmbi.2000.4322] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 3.5] [Reference Citation Analysis]
137 Méplan C, Verhaegh G, Richard MJ, Hainaut P. Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis. Proc Nutr Soc 1999;58:565-71. [PMID: 10604188 DOI: 10.1017/s0029665199000749] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
138 Dinjens WNM, van der Burg MEL, Chadha S, Sleddens HFBM, Burger CW, Ewing PC. Clinical importance of molecular determinations in gynecologic patients with multiple tumors. Cancer 2003;97:1766-74. [DOI: 10.1002/cncr.11249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
139 Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000;462:335-342. [PMID: 10767643 DOI: 10.1016/s1383-5742(00)00019-3] [Cited by in Crossref: 139] [Cited by in F6Publishing: 70] [Article Influence: 6.3] [Reference Citation Analysis]
140 Lothe RA, Smith-sørensen B, Hektoen M, Stenwig AE, Mandahl N, Sæter G, Mertens F. Biallelic inactivation ofTP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosom Cancer 2001;30:202-6. [DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1079>3.0.co;2-5] [Cited by in Crossref: 41] [Article Influence: 2.0] [Reference Citation Analysis]
141 Kelly JD, Inga A, Chen F, Dande P, Shah D, Monti P, Aprile A, Burns PA, Scott G, Abbondandolo A, Gold B, Fronza G. Relationship between DNA Methylation and Mutational Patterns Induced by a Sequence Selective Minor Groove Methylating Agent. Journal of Biological Chemistry 1999;274:18327-34. [DOI: 10.1074/jbc.274.26.18327] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 1.1] [Reference Citation Analysis]
142 Khaliq S, Hameed A, Khaliq T, Ayub Q, Qamar R, Mohyuddin A, Mazhar K, Qasim-Mehdi S. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 2000;4:23-9. [PMID: 10794357 DOI: 10.1089/109065700316435] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
143 Huang W, Huang H, Liao AC, Shiue Y, Tai H, Lin C, Wang Y, Lin C, Shen K, Li C. Primary urothelial carcinoma of the upper tract: Important clinicopathological factors predicting bladder recurrence after surgical resection. Pathology International 2009;59:642-9. [DOI: 10.1111/j.1440-1827.2009.02420.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
144 Robert V, Michel P, Flaman JM, Chiron A, Martin C, Charbonnier F, Paillot B, Frebourg T. High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis. 2000;21:563-565. [PMID: 10753186 DOI: 10.1093/carcin/21.4.563] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 1.5] [Reference Citation Analysis]
145 Chin D, Boyle GM, Theile DR, Parsons PG, Coman WB. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. British Journal of Plastic Surgery 2004;57:595-602. [DOI: 10.1016/j.bjps.2004.06.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
146 Pollett A, Bedard YC, Li SQ, Rohan T, Kandel R. Correlation of p53 mutations in ThinPrep-processed fine needle breast aspirates with surgically resected breast cancers. Mod Pathol 2000;13:1173-9. [PMID: 11106073 DOI: 10.1038/modpathol.3880216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
147 Imbriano C, Gnesutta N, Mantovani R. The NF-Y/p53 liaison: well beyond repression. Biochim Biophys Acta 2012;1825:131-9. [PMID: 22138487 DOI: 10.1016/j.bbcan.2011.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
148 Noori P, Hou S. Mutational spectrum induced by acetaldehyde in the HPRT gene of human T lymphocytes resembles that in the p53 gene of esophageal cancers. Carcinogenesis 2001;22:1825-30. [DOI: 10.1093/carcin/22.11.1825] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
149 Tu Y, Dammann R, Pfeifer GP. Sequence and time-dependent deamination of cytosine bases in UVB-induced cyclobutane pyrimidine dimers in vivo. Journal of Molecular Biology 1998;284:297-311. [DOI: 10.1006/jmbi.1998.2176] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 3.0] [Reference Citation Analysis]
150 Briese J, Schulte HM, Sajin M, Bamberger C, Redlin K, Milde-Langosch K, Löning T, Bamberger AM. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. Virchows Arch 2008;453:89-96. [PMID: 18415123 DOI: 10.1007/s00428-008-0608-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
151 Wang XJ, Yuan SL, Li CP, Iida N, Oda H, Aiso S, Ishikawa T. Infrequent p53 gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China. World J Gastroenterol 2000; 6(5): 750-753 [PMID: 11819688 DOI: 10.3748/wjg.v6.i5.750] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
152 Megha T, Ferrari F, Benvenuto A, Bellan C, Lalinga AV, Lazzi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 2002;55:461-6. [PMID: 12037031 DOI: 10.1136/jcp.55.6.461] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
153 Manikandan M, Raksha G, Munirajan AK. Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach. Cancer Inform 2012;11:157-71. [PMID: 23032637 DOI: 10.4137/CIN.S10176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
154 Lv T, Lv H, Fei J, Xie Y, Lian D, Hu J, Tang L, Shi X, Wang J, Zhang S, Li F, Jiang X, Yi Y. p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1. J Cancer 2020;11:6874-82. [PMID: 33123278 DOI: 10.7150/jca.44718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Olotu FA, Soliman MES. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy. J Cell Biochem 2019;120:951-66. [PMID: 30160791 DOI: 10.1002/jcb.27458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
156 Kozack R, Seo KY, Jelinsky SA, Loechler EL. Toward an understanding of the role of DNA adduct conformation in defining mutagenic mechanism based on studies of the major adduct (formed at N(2)-dG) of the potent environmental carcinogen, benzo[a]pyrene. Mutat Res 2000;450:41-59. [PMID: 10838133 DOI: 10.1016/s0027-5107(00)00015-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
157 Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000;11:307-13. [PMID: 10811497 DOI: 10.1023/a:1008340723974] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
158 Liu H, Wang M, Diao S, Rao Q, Zhang X, Xing H, Wang J. siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk Res 2009;33:1243-8. [PMID: 19299014 DOI: 10.1016/j.leukres.2009.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
159 Koike M, Fujita F, Komori K, Katoh F, Sugimoto T, Sakamoto Y, Matsuda M, Fujita M. Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Science 2004;95:541-6. [DOI: 10.1111/j.1349-7006.2004.tb03246.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
160 Mendrysa SM, Perry ME. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol. 2000;20:2023-2030. [PMID: 10688649 DOI: 10.1128/MCB.20.6.2023-2030.2000] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
161 Pradhan S, Das S, Singh AK, Das C, Basu A, Majumder PP, Biswas NK. dbGENVOC: database of GENomic Variants of Oral Cancer, with special reference to India. Database (Oxford) 2021;2021:baab034. [PMID: 34048545 DOI: 10.1093/database/baab034] [Reference Citation Analysis]
162 Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis 2003;6:281-5. [PMID: 14663467 DOI: 10.1038/sj.pcan.4500665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
163 Hernandez-boussard T, Montesano R, Hainaut P. Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. Genetic Analysis: Biomolecular Engineering 1999;14:229-33. [DOI: 10.1016/s1050-3862(98)00030-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
164 Borska L, Andrys C, Krejsek J, Hamakova K, Kremlacek J, Ranna D, Kotingova L, Fiala Z. Plasma levels of p53 protein and chromosomal aberrations in patients with psoriasis treated with the Goeckerman regimen. Clinical and Experimental Dermatology 2009;34:e881-3. [DOI: 10.1111/j.1365-2230.2009.03648.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
165 Brázda V, Paleĉek J, Pospísilová S, Vojtêsek B, Paleĉek E. Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies. Biochem Biophys Res Commun 2000;267:934-9. [PMID: 10673394 DOI: 10.1006/bbrc.1999.2056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
166 Ide F, Oda H, Nakatsuru Y, Kusama K, Sakashita H, Tanaka K, Ishikawa T. Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis. Carcinogenesis 2001;22:567-72. [DOI: 10.1093/carcin/22.4.567] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
167 Xu Z, Shu H, Zhang F, Luo W, Li Y, Chu J, Zhao Q, Lv Y. Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma. Front Oncol 2020;10:1327. [PMID: 32850421 DOI: 10.3389/fonc.2020.01327] [Reference Citation Analysis]
168 Wu L, Yu H, Zhao Y, Zhang C, Wang J, Yue X, Yang Q, Hu W. HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget 2015;6:4406-17. [PMID: 25726527 DOI: 10.18632/oncotarget.3017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
169 Prescott J, Patel H, Tillman S, Mchugh T, Ralph D. Cleavage of double-stranded copy RNA by RNase 1 and RNase T 1 provides a robust means to detectp53 gene mutations in clinical specimens. Electrophoresis 1999;20:1149-61. [DOI: 10.1002/(sici)1522-2683(19990101)20:6<1149::aid-elps1149>3.0.co;2-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Wang Y, Schlick T. Distinct energetics and closing pathways for DNA polymerase beta with 8-oxoG template and different incoming nucleotides. BMC Struct Biol 2007;7:7. [PMID: 17313689 DOI: 10.1186/1472-6807-7-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
171 Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies: Clonality of Multifocal Urothelial Carcinomas. Int J Cancer 2002;101:1-6. [DOI: 10.1002/ijc.10544] [Cited by in Crossref: 127] [Cited by in F6Publishing: 100] [Article Influence: 6.4] [Reference Citation Analysis]
172 Müller-Ladner U, Nishioka K. p53 in rheumatoid arthritis: friend or foe? Arthritis Res 2000;2:175-8. [PMID: 11094424 DOI: 10.1186/ar82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
173 Hara Y, Zheng Z, Evans SC, Malatjalian D, Riddell DC, Guernsey DL, Wang LD, Riabowol K, Casson AG. ING1 and p53 tumor suppressor gene alterations in adenocarcinomas of the esophagogastric junction. Cancer Lett. 2003;192:109-116. [PMID: 12637159 DOI: 10.1016/s0304-3835(02)00635-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
174 Eliaš J, Macnamara CK. Mathematical Modelling of p53 Signalling during DNA Damage Response: A Survey. Int J Mol Sci 2021;22:10590. [PMID: 34638930 DOI: 10.3390/ijms221910590] [Reference Citation Analysis]
175 Yoshida T, Mikami T, Mitomi H, Okayasu I. Diverse p53 alterations in ulcerative colitis-associated low-grade dysplasia: full-length gene sequencing in microdissected single crypts. J Pathol 2003;199:166-75. [PMID: 12533829 DOI: 10.1002/path.1264] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
176 Leroy K, Haioun C, Lepage E, Le Métayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G, Gisselbrecht C, Reyes F, Gaulard P; Groupe d'Etude des Lymphomes de l'Adulte. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002;13:1108-15. [PMID: 12176791 DOI: 10.1093/annonc/mdf185] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 3.5] [Reference Citation Analysis]
177 Sharma A, Kar A, Kaur M, Ranade SM, Sankaran A, Misra S, Rawat K, Saxena S. Specific replication factors are targeted by different genotoxic agents to inhibit replication. IUBMB Life 2010;62:764-75. [PMID: 20945455 DOI: 10.1002/iub.380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
178 Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncology 2003;39:213-21. [DOI: 10.1016/s1368-8375(02)00162-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
179 Egashira A, Morita M, Yoshida R, Saeki H, Oki E, Sadanaga N, Kakeji Y, Tsujitani S, Maehara Y. Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients. J Surg Oncol. 2011;104:169-175. [PMID: 21462189 DOI: 10.1002/jso.21920] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
180 Kawasaki K, Suzuki1 T, Ueda M, Ichihashi M, Reguer G, Yamasaki H. CC to TT mutation in the mitochondrial DNA of normal skin: relationship to ultraviolet light exposure. Mutat Res 2000;468:35-43. [PMID: 10863156 DOI: 10.1016/s1383-5718(00)00038-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
181 Omar SI, Tuszynski J. Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties. Chem Biol Drug Des 2015;86:163-72. [DOI: 10.1111/cbdd.12480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
182 Bentley DP, Pepper CJ. The apoptotic pathway: a target for therapy in chronic lymphocytic leukemia. Hematol Oncol 2000;18:87-98. [PMID: 11027978 DOI: 10.1002/1099-1069(200009)18:3<87::aid-hon661>3.0.co;2-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
183 Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trépo C, Bréchot C, Hainaut P, Montesano R. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst. 2000;92:148-153. [PMID: 10639517 DOI: 10.1093/jnci/92.2.148] [Cited by in Crossref: 117] [Cited by in F6Publishing: 99] [Article Influence: 5.3] [Reference Citation Analysis]
184 Hsieh PC, Chang JC, Sun WT, Hsieh SC, Wang MC, Wang FF. p53 downstream target DDA3 is a novel microtubule-associated protein that interacts with end-binding protein EB3 and activates beta-catenin pathway. Oncogene 2007;26:4928-40. [PMID: 17310996 DOI: 10.1038/sj.onc.1210304] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
185 Jagelská EB, Brázda V, Pecinka P, Palecek E, Fojta M. DNA topology influences p53 sequence-specific DNA binding through structural transitions within the target sites. Biochem J 2008;412:57-63. [PMID: 18271758 DOI: 10.1042/BJ20071648] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
186 Chen J, Xie F, Zhang L, Jiang WG. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer 2010;10:694. [PMID: 21192816 DOI: 10.1186/1471-2407-10-694] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
187 Yang Q, Wesch H, Mueller KM, Bartsch H, Wegener K, Hollstein M. Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hotspot mutation. Br J Cancer 2000;82:763-6. [PMID: 10732742 DOI: 10.1054/bjoc.1999.0995] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
188 Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov 2011;1:312-25. [PMID: 22586610 DOI: 10.1158/2159-8290.CD-11-0104] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
189 Hanrahan EO, Glisson B. Small Cell Carcinoma of the Lung. In: Stewart DJ, editor. Lung Cancer. Totowa: Humana Press; 2010. pp. 395-434. [DOI: 10.1007/978-1-60761-524-8_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
190 Oğuztüzün S, Sezgin Y, Yazıcı S, Fırat P, Ozhavzalı M, Ozen H. Expression of glutathione-S-transferases isoenzymes and p53 in exfoliated human bladder cancer cells. Urol Oncol 2011;29:538-44. [PMID: 19926314 DOI: 10.1016/j.urolonc.2009.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
191 Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012;11:4579-88. [PMID: 23187804 DOI: 10.4161/cc.22852] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
192 Jung HS, Rajasekaran N, Song SY, Kim YD, Hong S, Choi HJ, Kim YS, Choi JS, Choi YL, Shin YK. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci 2015;16:12243-60. [PMID: 26035754 DOI: 10.3390/ijms160612243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
193 Benor G, Fuks G, Chin SF, Rueda OM, Mukherjee S, Arandkar S, Aylon Y, Caldas C, Domany E, Oren M. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features. Mol Oncol 2020;14:1640-52. [PMID: 32484602 DOI: 10.1002/1878-0261.12736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Hostanska K, Vuong V, Rocha S, Soengas MS, Glanzmann C, Saller R, Bodis S, Pruschy M. Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. Br J Cancer 2003;88:1785-92. [PMID: 12771996 DOI: 10.1038/sj.bjc.6600982] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
195 Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, Landi S. DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat 2010;31:456-65. [PMID: 20127977 DOI: 10.1002/humu.21214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
196 Kato T, Kolenic N, Pardini RS. Docosahexaenoic Acid (DHA), a Primary Tumor Suppressive Omega-3 Fatty Acid, Inhibits Growth of Colorectal Cancer Independent of p53 Mutational Status. Nutrition and Cancer 2007;58:178-87. [DOI: 10.1080/01635580701328362] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
197 Waters TR, Swann PF. Thymine-DNA glycosylase and G to A transition mutations at CpG sites. Mutation Research/Reviews in Mutation Research 2000;462:137-47. [DOI: 10.1016/s1383-5742(00)00031-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
198 Goan Y, Chang H, Hsu H, Chou Y, Cheng J. Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese. Cancer Science 2005;96:758-65. [DOI: 10.1111/j.1349-7006.2005.00115.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
199 Daher T, Tur MK, Brobeil A, Etschmann B, Witte B, Engenhart-Cabillic R, Krombach G, Blau W, Grimminger F, Seeger W, Klussmann JP, Bräuninger A, Gattenlöhner S. Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Head Neck 2018;40:1109-19. [PMID: 29522268 DOI: 10.1002/hed.25041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
200 Pfeifer GP, Tang M, Denissenko MF. Mutation Hotspots and DNA Methylation. In: Jones PA, Vogt PK, editors. DNA Methylation and Cancer. Berlin: Springer Berlin Heidelberg; 2000. pp. 1-19. [DOI: 10.1007/978-3-642-59696-4_1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
201 Chappuis PO, Estreicher A, Dieterich B, Bonnefoi H, Otter M, Sappino A, Iggo R. Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999;84:587-93. [DOI: 10.1002/(sici)1097-0215(19991222)84:6<587::aid-ijc8>3.0.co;2-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
202 Lane D. Exploiting the p53 Pathway for the Diagnosis and Therapy of Human Cancer. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:489-97. [DOI: 10.1101/sqb.2005.70.049] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
203 Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surgery Clinics of North America 2002;12:93-111. [DOI: 10.1016/s1052-3359(03)00068-1] [Cited by in Crossref: 13] [Article Influence: 0.7] [Reference Citation Analysis]
204 Bazrafshani MR, Nowshadi PA, Shirian S, Daneshbod Y, Nabipour F, Mokhtari M, Hosseini F, Dehghan S, Saeedzadeh A, Mosayebi Z. Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation-dependent probe amplification. Cancer Med 2016;5:145-52. [PMID: 26685928 DOI: 10.1002/cam4.561] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
205 Takagi M, Absalon MJ, Mclure KG, Kastan MB. Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin. Cell 2005;123:49-63. [DOI: 10.1016/j.cell.2005.07.034] [Cited by in Crossref: 442] [Cited by in F6Publishing: 427] [Article Influence: 26.0] [Reference Citation Analysis]
206 Berggren P, Steineck G, Hemminki K. A rapid fluorescence based multiplex polymerase chain reaction — single-strand conformation polymorphism method forp53 mutation detection. Electrophoresis 2000;21:2335-42. [DOI: 10.1002/1522-2683(20000701)21:12<2335::aid-elps2335>3.0.co;2-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
207 Hiraga J, Kinoshita T, Ohno T, Mori N, Ohashi H, Fukami S, Noda A, Ichikawa A, Naoe T. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol 2006;84:248-55. [PMID: 17050200 DOI: 10.1532/IJH97.06087] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
208 Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999;14:1-8. [PMID: 10447253 DOI: 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1>3.0.CO;2-H] [Cited by in Crossref: 110] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
209 Lang S, Marchesani M, Servomaa K, Kauppinen L, Jänne J, Rytömaa T, Wells R, Lun M, Elkind M. p53 gene mutations in neoplastic transformation of C3H 10T1/2 and severe combined immunodeficiency fibroblasts. Mutation Research/DNA Repair 1999;434:61-5. [DOI: 10.1016/s0921-8777(99)00018-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
210 Yarbrough WG. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope 2002;112:2114-28. [PMID: 12461329 DOI: 10.1097/00005537-200212000-00002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
211 Jung HS, Rajasekaran N, Ju W, Shin YK. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J Clin Med 2015;4:1126-55. [PMID: 26239469 DOI: 10.3390/jcm4051126] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
212 Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 2005;25:10097-110. [PMID: 16260623 DOI: 10.1128/MCB.25.22.10097-10110.2005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
213 Barakat K, Issack BB, Stepanova M, Tuszynski J. Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. PLoS One 2011;6:e27651. [PMID: 22110706 DOI: 10.1371/journal.pone.0027651] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
214 Ji J, Wu K, Wu M, Zhan Q. p53 functional activation is independent of its genotype in five esophageal squamous cell carcinoma cell lines. Front Med China 2010;4:412-8. [PMID: 21191746 DOI: 10.1007/s11684-010-0260-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
215 Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 2008;104:1124-49. [PMID: 18459149 DOI: 10.1002/jcb.21707] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 7.4] [Reference Citation Analysis]
216 Veiga LC, Bérgamo NA, Kowalski LP, Rogatto SR. Classical and molecular cytogenetic analysis in head and neck squamous cell carcinomas. Genet Mol Biol 2003;26:121-8. [DOI: 10.1590/s1415-47572003000200003] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
217 King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 2000;89:769-73. [DOI: 10.1002/1097-0142(20000815)89:4<769::aid-cncr8>3.0.co;2-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
218 Glazko GV, Koonin EV, Rogozin IB. Mutation hotspots in the p53 gene in tumors of different origin: correlation with evolutionary conservation and signs of positive selection. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 2004;1679:95-106. [DOI: 10.1016/j.bbaexp.2004.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
219 Wingender E, Chen X, Fricke E, Geffers R, Hehl R, Liebich I, Krull M, Matys V, Michael H, Ohnhäuser R, Prüss M, Schacherer F, Thiele S, Urbach S. The TRANSFAC system on gene expression regulation. Nucleic Acids Res 2001;29:281-3. [PMID: 11125113 DOI: 10.1093/nar/29.1.281] [Cited by in Crossref: 408] [Cited by in F6Publishing: 410] [Article Influence: 19.4] [Reference Citation Analysis]
220 Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. British Journal of Haematology 2009;146:257-69. [DOI: 10.1111/j.1365-2141.2009.07739.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
221 Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Worsham MJ. Significance of p53 mutations in patients with chronic lymphocytic leukemia: A sequential study of 30 patients. Cancer 2001;91:285-93. [DOI: 10.1002/1097-0142(20010115)91:2<285::aid-cncr1000>3.0.co;2-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
222 Mayr B, Resch S, Hepperle S, Brem G, Reifinger M, Schaffner G. Comparative Studies in the Promoter and Exon 1 Regions of Tumour Suppressor p53 in Several Mammalian Species: Absence of Mutations in a Panel of Spontaneous Domestic Animal Tumours. J Vet Med Series A 2000;47:593-7. [DOI: 10.1046/j.1439-0442.2000.00322.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
223 Graziani D, Romagnoli S, Cassani B, Alfano RM, Roncalli M, Coggi G. An Ava I polymorphism in the TP53 gene. Mol Cell Probes 1999;13:393-5. [PMID: 10508562 DOI: 10.1006/mcpr.1999.0256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
224 Deng Y, Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci USA. 2000;97:12050-12055. [PMID: 11050235 DOI: 10.1073/pnas.97.22.12050] [Cited by in Crossref: 126] [Cited by in F6Publishing: 135] [Article Influence: 5.7] [Reference Citation Analysis]
225 Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst. 2000;92:803-811. [PMID: 10814675 DOI: 10.1093/jnci/92.10.803] [Cited by in Crossref: 189] [Cited by in F6Publishing: 168] [Article Influence: 8.6] [Reference Citation Analysis]
226 Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007;117:2740-50. [PMID: 17909619 DOI: 10.1172/JCI31809] [Cited by in Crossref: 144] [Cited by in F6Publishing: 88] [Article Influence: 9.6] [Reference Citation Analysis]
227 Hao J, Song X, Song B, Liu Y, Wei L, Wang X, Yu J. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 2008;15:449-55. [PMID: 18421307 DOI: 10.1038/cgt.2008.4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
228 Castro PD, Liang JC, Nagarajan L. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 2000;95:2138-43. [DOI: 10.1182/blood.v95.6.2138] [Cited by in Crossref: 47] [Article Influence: 2.1] [Reference Citation Analysis]
229 Jung HS, Erkin OC, Kwon MJ, Kim SH, Jung JI, Oh YK, Her SW, Ju W, Choi YL, Song SY, Kim JK, Kim YD, Shim GY, Shin YK. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int J Cancer 2012;130:1925-36. [PMID: 21630254 DOI: 10.1002/ijc.26197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
230 Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 2010;17:982-9. [PMID: 20639885 DOI: 10.1038/nsmb.1872] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 8.0] [Reference Citation Analysis]
231 Guerra E, Cimadamore A, Simeone P, Vacca G, Lattanzio R, Botti G, Gatta V, D'Aurora M, Simionati B, Piantelli M, Alberti S. p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer 2016;16:649. [PMID: 27538498 DOI: 10.1186/s12885-016-2713-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
232 Pankow S, Bamberger C. The p53 tumor suppressor-like protein nvp63 mediates selective germ cell death in the sea anemone Nematostella vectensis. PLoS One 2007;2:e782. [PMID: 17848985 DOI: 10.1371/journal.pone.0000782] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
233 Bitton A, Neuman MD, Barnoya J, Glantz SA. The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest. The Lancet 2005;365:531-40. [DOI: 10.1016/s0140-6736(05)17871-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
234 Das P, Kotilingam D, Korchin B, Liu J, Yu D, Lazar AJ, Pollock RE, Lev D. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 2007;109:2323-33. [PMID: 17429838 DOI: 10.1002/cncr.22680] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
235 Ridgeway AG, McMenamin J, Leder P. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells. Oncogene 2006;25:3518-27. [PMID: 16434961 DOI: 10.1038/sj.onc.1209391] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
236 Hayes VM, Bleeker W, Verlind E, Timmer T, Karrenbeld A, Plukker JT, Marx MP, Hofstra RMW, Buys CHCM. Comprehensive TP53-Denaturing Gradient Gel Electrophoresis Mutation Detection Assay Also Applicable to Archival Paraffin-Embedded Tissue: . Diagnostic Molecular Pathology 1999;8:2-10. [DOI: 10.1097/00019606-199903000-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
237 Singhal P, Tchabo NE, Odunsi K. Immunologic markers of cancer progression and prognosis. Expert Opin Med Diagn 2007;1:439-50. [PMID: 23496352 DOI: 10.1517/17530059.1.4.439] [Reference Citation Analysis]
238 Boon EM, Ceres DM, Drummond TG, Hill MG, Barton JK. Mutation detection by electrocatalysis at DNA-modified electrodes. Nat Biotechnol 2000;18:1096-100. [PMID: 11017050 DOI: 10.1038/80301] [Cited by in Crossref: 492] [Cited by in F6Publishing: 443] [Article Influence: 22.4] [Reference Citation Analysis]
239 Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg. 2003;125:1121-1131. [PMID: 12771886 DOI: 10.1067/mtc.2003.176] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
240 Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137. [PMID: 10549356 DOI: 10.1016/s0065-230x(08)60785-x] [Cited by in Crossref: 572] [Cited by in F6Publishing: 260] [Article Influence: 24.9] [Reference Citation Analysis]
241 Fredrik JB, Hein FBMS, Winand NMD. Molecular Assessment of Clonality Leads to the Identification of a New Germ Line TP53 Mutation Associated With Malignant Cystosarcoma Phyllodes and Soft Tissue Sarcoma: . Diagnostic Molecular Pathology 1998;7:295-301. [DOI: 10.1097/00019606-199812000-00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
242 Ling G, Persson A, Berne B, Uhlén M, Lundeberg J, Ponten F. Persistent p53 mutations in single cells from normal human skin. Am J Pathol 2001;159:1247-53. [PMID: 11583952 DOI: 10.1016/S0002-9440(10)62511-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
243 Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkström H, Hemminki K. p53 mutations in urinary bladder cancer. Br J Cancer 2001;84:1505-11. [PMID: 11384101 DOI: 10.1054/bjoc.2001.1823] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
244 Ferrer-Costa C, Orozco M, de la Cruz X. Sequence-based prediction of pathological mutations. Proteins 2004;57:811-9. [PMID: 15390262 DOI: 10.1002/prot.20252] [Cited by in Crossref: 135] [Cited by in F6Publishing: 130] [Article Influence: 8.4] [Reference Citation Analysis]
245 Boivin-Angele S, Pedron S, Bertrand S, Desmouliere A, Martel-Planche G, Lefrançois L, Bancel B, Trépo C, Marion MJ. Establishment and characterization of a spontaneously immortalized myofibroblast cell line derived from a human liver angiosarcoma. J Hepatol 2000;33:290-300. [PMID: 10952247 DOI: 10.1016/s0168-8278(00)80370-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
246 Darnton SJ. Demystified ... p53. Mol Pathol 1998;51:248-53. [PMID: 10193518 DOI: 10.1136/mp.51.5.248] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
247 Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith D, Goh H, Joseph D, Iacopetta B. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. European Journal of Cancer 2000;36:2053-60. [DOI: 10.1016/s0959-8049(00)00285-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
248 Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529-535. [PMID: 15548361 DOI: 10.1593/neo.04178] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
249 Kim YK, Koo NY, Yun PY. Anticancer effects of CKD-602 (Camtobell®) via G2/M phase arrest in oral squamous cell carcinoma cell lines. Oncol Lett 2015;9:136-42. [PMID: 25435947 DOI: 10.3892/ol.2014.2648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
250 Klumb CE, Furtado DR, de Resende LM, Carriço MK, Coelho AM, de Meis E, Maia RC, Rumjanek FD. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur J Haematol 2003;71:81-90. [PMID: 12890146 DOI: 10.1034/j.1600-0609.2003.00094.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
251 Foo RS, Nam YJ, Ostreicher MJ, Metzl MD, Whelan RS, Peng CF, Ashton AW, Fu W, Mani K, Chin SF, Provenzano E, Ellis I, Figg N, Pinder S, Bennett MR, Caldas C, Kitsis RN. Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A 2007;104:20826-31. [PMID: 18087040 DOI: 10.1073/pnas.0710017104] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
252 Kennedy AS, Harrison GH, Mansfield CM, Zhou XJ, Xu JF, Balcer-kubiczek EK. Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: Effect of TP53 or hMLH1 deficiency. Int J Cancer 2000;90:175-85. [DOI: 10.1002/1097-0215(20000820)90:4<175::aid-ijc1>3.0.co;2-w] [Cited by in Crossref: 16] [Article Influence: 0.7] [Reference Citation Analysis]
253 Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S, Trikalinos TA. Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol 2013;177:1317-25. [PMID: 23729685 DOI: 10.1093/aje/kws394] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
254 Kösel S, Scheithauer BW, Graeber MB. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 2001;48:187-93; discussion 193-4. [PMID: 11152345 DOI: 10.1097/00006123-200101000-00033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
255 Hirose M, Yamato K, Endo S, Saito R, Ueno T, Hirai S, Suzuki H, Abei M, Natori Y, Hyodo I. MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. Oncoscience 2014;1:830-43. [PMID: 25621298 DOI: 10.18632/oncoscience.103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
256 Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S, Seifeldin IA, Houlihan PS, Lukish JR, Watanabe T. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer. 2001;85:1037-1046. [PMID: 11592777 DOI: 10.1038/sj.bjc.6691838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
257 Chen L, Chu C, Lu J, Kong X, Huang T, Cai YD. A computational method for the identification of new candidate carcinogenic and non-carcinogenic chemicals. Mol Biosyst 2015;11:2541-50. [PMID: 26194467 DOI: 10.1039/c5mb00276a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
258 Strauss BS. Role in tumorigenesis of silent mutations in the TP53 gene. Mutat Res 2000;457:93-104. [PMID: 11106801 DOI: 10.1016/s0027-5107(00)00135-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
259 Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol 2004;31:4-19. [PMID: 14981576 DOI: 10.1053/j.seminoncol.2003.12.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
260 Backvall H, Wolf O, Hermelin H, Weitzberg E, Ponten F. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma. Br J Dermatol 2004;150:259-66. [DOI: 10.1111/j.1365-2133.2004.05683.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
261 Fuster JJ, Sanz-González SM, Moll UM, Andrés V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007;13:192-9. [PMID: 17383232 DOI: 10.1016/j.molmed.2007.03.002] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.5] [Reference Citation Analysis]
262 Ramani RG, Jacob SG. Prediction of P53 mutants (multiple sites) transcriptional activity based on structural (2D&3D) properties. PLoS One 2013;8:e55401. [PMID: 23468845 DOI: 10.1371/journal.pone.0055401] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
263 Bethuyne J, De Gieter S, Zwaenepoel O, Garcia-Pino A, Durinck K, Verhelle A, Hassanzadeh-Ghassabeh G, Speleman F, Loris R, Gettemans J. A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. Nucleic Acids Res 2014;42:12928-38. [PMID: 25324313 DOI: 10.1093/nar/gku962] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
264 Kühne C, Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem 1998;273:34302-9. [PMID: 9852095 DOI: 10.1074/jbc.273.51.34302] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 5.3] [Reference Citation Analysis]
265 Marrogi AJ, Khan MA, Vonderheid EC, Wood GS, Mcburney E. p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: A study of 12 cases. J Cutan Pathol 1999;26:369-78. [DOI: 10.1111/j.1600-0560.1999.tb01860.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
266 Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 2000;53:24-30. [PMID: 10884918 DOI: 10.1136/mp.53.1.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
267 Cuff AL, Martin AC. Analysis of void volumes in proteins and application to stability of the p53 tumour suppressor protein. J Mol Biol 2004;344:1199-209. [PMID: 15561139 DOI: 10.1016/j.jmb.2004.10.015] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
268 Jarvis IW, Dreij K, Mattsson Å, Jernström B, Stenius U. Interactions between polycyclic aromatic hydrocarbons in complex mixtures and implications for cancer risk assessment. Toxicology 2014;321:27-39. [PMID: 24713297 DOI: 10.1016/j.tox.2014.03.012] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 12.4] [Reference Citation Analysis]
269 Tayarani-Najaran Z, Mousavi SH, Vahdati-Mashhadian N, Emami SA, Parsaee H. Scutellaria litwinowii induces apoptosis through both extrinsic and intrinsic apoptotic pathways in human promyelocytic leukemia cells. Nutr Cancer 2012;64:80-8. [PMID: 22098153 DOI: 10.1080/01635581.2012.630162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
270 Moodley D, Mody GM, Chuturgoon AA. Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis—a pilot study. Clin Rheumatol 2010;29:1099-105. [DOI: 10.1007/s10067-010-1505-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
271 Chan JY, Chen YC, Liu ST, Chou WY, Ho CL, Huang SM. Characterization of a new mouse p53 variant: loss-of-function and gain-of-function. J Biomed Sci 2014;21:40. [PMID: 24884657 DOI: 10.1186/1423-0127-21-40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
272 Lu X, Feki A. Phenotypic features with p53 alterations related to human papillomavirus and prognostic evaluation in cervical cancer. Int J Gynecol Cancer 2006;16:708-17. [PMID: 16681751 DOI: 10.1111/j.1525-1438.2006.00591.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
273 Liu G, Chen X. Regulation of the p53 transcriptional activity. J Cell Biochem 2006;97:448-58. [DOI: 10.1002/jcb.20700] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 4.4] [Reference Citation Analysis]
274 Khafizov K, Ivanov MV, Glazova OV, Kovalenko SP. Computational approaches to study the effects of small genomic variations. J Mol Model 2015;21:251. [PMID: 26350246 DOI: 10.1007/s00894-015-2794-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
275 Beckman J, Wang M, Blaha G, Wang J, Konigsberg WH. Substitution of Ala for Tyr567 in RB69 DNA polymerase allows dAMP to be inserted opposite 7,8-dihydro-8-oxoguanine . Biochemistry 2010;49:4116-25. [PMID: 20411947 DOI: 10.1021/bi100102s] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
276 Wang CS, Goulet F, Lavoie J, Drouin R, Auger F, Champetier S, Germain L, Têtu B. Establishment and characterization of a new cell line derived from a human primary breast carcinoma. Cancer Genet Cytogenet 2000;120:58-72. [PMID: 10913678 DOI: 10.1016/s0165-4608(99)00253-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
277 Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk G, Friedman L, Prives C, Kopczynski C. Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53. Cell 2000;101:91-101. [DOI: 10.1016/s0092-8674(00)80626-1] [Cited by in Crossref: 279] [Cited by in F6Publishing: 150] [Article Influence: 12.7] [Reference Citation Analysis]
278 Wang Y, Reddy S, Beard WA, Wilson SH, Schlick T. Differing conformational pathways before and after chemistry for insertion of dATP versus dCTP opposite 8-oxoG in DNA polymerase beta. Biophys J 2007;92:3063-70. [PMID: 17293403 DOI: 10.1529/biophysj.106.092106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
279 Brázdová M, Palecek J, Cherny DI, Billová S, Fojta M, Pecinka P, Vojtesek B, Jovin TM, Palecek E. Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Res 2002;30:4966-74. [PMID: 12434001 DOI: 10.1093/nar/gkf616] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 2.6] [Reference Citation Analysis]
280 Nachtergael A, Charles C, Spanoghe M, Gadenne M, Belayew A, Duez P. Measurement of translesion synthesis by fluorescent capillary electrophoresis: 7,8-dihydro-8-oxodeoxyguanosine bypass modulation by natural products. Anal Biochem 2013;440:23-31. [PMID: 23711721 DOI: 10.1016/j.ab.2013.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
281 Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutation Research/Reviews in Mutation Research 2002;511:45-62. [DOI: 10.1016/s1383-5742(01)00075-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
282 Zheng XT, Goh WL, Yeow P, Lane DP, Ghadessy FJ, Tan YN. Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening. Sensors and Actuators B: Chemical 2019;279:79-86. [DOI: 10.1016/j.snb.2018.09.088] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
283 Javadi H, Lotfi AS, Hosseinkhani S, Mehrani H, Amani J, Soheili ZS, Hojati Z, Kamali M. The combinational effect of E6/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells. Artif Cells Nanomed Biotechnol 2018;46:727-36. [PMID: 29873516 DOI: 10.1080/21691401.2018.1468770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
284 Lehv�slaiho H, Stupka E, Ashburner M. Sequence variation database project at the European Bioinformatics Institute. Hum Mutat 2000;15:52-6. [DOI: 10.1002/(sici)1098-1004(200001)15:1<52::aid-humu11>3.0.co;2-y] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
285 Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL, Simon MC. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 2009;106:14391-6. [PMID: 19706526 DOI: 10.1073/pnas.0907357106] [Cited by in Crossref: 128] [Cited by in F6Publishing: 129] [Article Influence: 9.8] [Reference Citation Analysis]
286 Ruggeri RM, Vicchio TM, Giovinazzo S, Certo R, Alibrandi A, Trimarchi F, Benvenga S, Trovato M. TP53 polymorphism may contribute to genetic susceptibility to develop Hashimoto's thyroiditis. J Endocrinol Invest 2015;38:1175-82. [PMID: 25935255 DOI: 10.1007/s40618-015-0292-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
287 Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes Cancer 2019;58:875-88. [DOI: 10.1002/gcc.22796] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
288 Husgafvel-pursiainen K, Karjalainen A, Kannio A, Anttila S, Partanen T, Ojajärvi A, Vainio H. Lung Cancer and Past Occupational Exposure to Asbestos: Role of p53 and K-ras Mutations. Am J Respir Cell Mol Biol 1999;20:667-74. [DOI: 10.1165/ajrcmb.20.4.3404] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
289 Rogozin I, Kondrashov F, Glazko G. Use of mutation spectra analysis software. Hum Mutat 2001;17:83-102. [PMID: 11180592 DOI: 10.1002/1098-1004(200102)17:2<83::AID-HUMU1>3.0.CO;2-E] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
290 Vos M, Adams CH, Victor TC, van Helden PD. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet. 2003;140:23-30. [PMID: 12550754 DOI: 10.1016/s0165-4608(02)00638-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
291 Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelman JH, Orentreich N, Habel LA. CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis. 2002;23:419-424. [PMID: 11895856 DOI: 10.1093/carcin/23.3.419] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 2.5] [Reference Citation Analysis]
292 Kim Y, Sills RC, Houle CD. Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol Pathol 2005;33:175-80. [PMID: 15805069 DOI: 10.1080/01926230590522130] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
293 Hussain S, Harris CC. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1999;428:23-32. [DOI: 10.1016/s1383-5742(99)00028-9] [Cited by in Crossref: 108] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
294 Hsu GW, Ober M, Carell T, Beese LS. Error-prone replication of oxidatively damaged DNA by a high-fidelity DNA polymerase. Nature 2004;431:217-21. [DOI: 10.1038/nature02908] [Cited by in Crossref: 221] [Cited by in F6Publishing: 216] [Article Influence: 12.3] [Reference Citation Analysis]
295 M�plan C, Hainaut P. Molecular alchemy of the tumor suppressor protein p53: Metals and cell growth control. J Trace Elem Exp Med 1999;12:337-46. [DOI: 10.1002/(sici)1520-670x(1999)12:4<337::aid-jtra7>3.0.co;2-j] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
296 Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S, Seifeldin IA, Houlihan PS, Lukish JR, Watanabe T, Chan AO, Zhu D, Amos CI, Levin B, Hamilton SR. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001;85:1037-46. [PMID: 11592777 DOI: 10.1054/bjoc.2001.1838] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
297 Pellerano M, Naud-Martin D, Mahuteau-Betzer F, Morille M, Morris MC. Fluorescent Biosensor for Detection of the R248Q Aggregation-Prone Mutant of p53. Chembiochem 2019;20:605-13. [PMID: 30548750 DOI: 10.1002/cbic.201800531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
298 Senoo M, Tsuchiya I, Matsumura Y, Mori T, Saito Y, Kato H, Okamoto T, Habu S. Transcriptional dysregulation of the p73L / p63 / p51 / p40 / KET gene in human squamous cell carcinomas: expression of Delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51. Br J Cancer 2001;84:1235-41. [PMID: 11336476 DOI: 10.1054/bjoc.2000.1735] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
299 Hao XP, Frayling IM, Sgouros JG, Du MQ, Willcocks TC, Talbot IC, Tomlinson IP. The spectrum of p53 mutations in colorectal adenomas differs from that in colorectal carcinomas. Gut 2002;50:834-9. [PMID: 12010886 DOI: 10.1136/gut.50.6.834] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
300 Havrilesky L, Darcy kM, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3814-3825. [PMID: 14551300 DOI: 10.1200/jco.2003.11.052] [Cited by in Crossref: 108] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
301 Hernandez T, Hainaut P. Tumor‐specific mutation spectra in the human p53 gene: From carcinogen “fingerprints” to functional consequences. Journal of Environmental Science and Health, Part C 1998;16:31-45. [DOI: 10.1080/10590509809373497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
302 Mayr B, Reifinger M, Alton K. Novel canine tumour suppressor gene p53 mutations in cases of skin and mammary neoplasms. Vet Res Commun 1999;23:285-91. [PMID: 10493115 DOI: 10.1023/a:1006314903272] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]